vs

Side-by-side financial comparison of CABOT CORP (CBT) and STEPAN CO (SCL). Click either name above to swap in a different company.

CABOT CORP is the larger business by last-quarter revenue ($849.0M vs $604.5M, roughly 1.4× STEPAN CO). CABOT CORP runs the higher net margin — 8.6% vs 3.3%, a 5.3% gap on every dollar of revenue. On growth, STEPAN CO posted the faster year-over-year revenue change (1.9% vs -11.1%). Over the past eight quarters, STEPAN CO's revenue compounded faster (4.2% CAGR vs -8.7%).

Cabot Corporation is an American specialty chemicals and performance materials company headquartered in Boston, Massachusetts. The company operates in over 20 countries with 36 manufacturing plants, eight research and development facilities, and 28 sales offices.

Stepan Company is an American manufacturer of specialty chemicals headquartered in Northbrook, Illinois. The company was founded in 1932 by Alfred C. Stepan, Jr., and has approximately 2,000 employees. It is currently run by his grandson, F. Quinn Stepan, Jr. The company describes itself as the largest global merchant manufacturer of anionic surfactants, which are used to enhance the foaming and cleaning capabilities of detergents, shampoos, toothpastes, and cosmetics.

CBT vs SCL — Head-to-Head

Bigger by revenue
CBT
CBT
1.4× larger
CBT
$849.0M
$604.5M
SCL
Growing faster (revenue YoY)
SCL
SCL
+13.0% gap
SCL
1.9%
-11.1%
CBT
Higher net margin
CBT
CBT
5.3% more per $
CBT
8.6%
3.3%
SCL
Faster 2-yr revenue CAGR
SCL
SCL
Annualised
SCL
4.2%
-8.7%
CBT

Income Statement — Q1 FY2026 vs Q1 FY2026

Metric
CBT
CBT
SCL
SCL
Revenue
$849.0M
$604.5M
Net Profit
$73.0M
$19.7M
Gross Margin
24.9%
10.7%
Operating Margin
15.2%
4.7%
Net Margin
8.6%
3.3%
Revenue YoY
-11.1%
1.9%
Net Profit YoY
-21.5%
EPS (diluted)
$1.37
$0.86

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CBT
CBT
SCL
SCL
Q1 26
$604.5M
Q4 25
$849.0M
$553.9M
Q3 25
$899.0M
$590.3M
Q2 25
$923.0M
$594.7M
Q1 25
$936.0M
$593.3M
Q4 24
$955.0M
$525.6M
Q3 24
$1.0B
$546.8M
Q2 24
$1.0B
$556.4M
Net Profit
CBT
CBT
SCL
SCL
Q1 26
$19.7M
Q4 25
$73.0M
$5.0M
Q3 25
$43.0M
$10.8M
Q2 25
$101.0M
$11.3M
Q1 25
$94.0M
$19.7M
Q4 24
$93.0M
$3.4M
Q3 24
$137.0M
$23.6M
Q2 24
$109.0M
$9.5M
Gross Margin
CBT
CBT
SCL
SCL
Q1 26
10.7%
Q4 25
24.9%
9.3%
Q3 25
24.5%
12.0%
Q2 25
26.4%
12.1%
Q1 25
25.7%
12.7%
Q4 24
24.6%
10.8%
Q3 24
24.0%
13.8%
Q2 24
25.2%
12.5%
Operating Margin
CBT
CBT
SCL
SCL
Q1 26
4.7%
Q4 25
15.2%
1.9%
Q3 25
15.2%
3.7%
Q2 25
18.1%
3.0%
Q1 25
17.3%
4.8%
Q4 24
16.2%
1.5%
Q3 24
15.0%
4.4%
Q2 24
16.9%
3.4%
Net Margin
CBT
CBT
SCL
SCL
Q1 26
3.3%
Q4 25
8.6%
0.9%
Q3 25
4.8%
1.8%
Q2 25
10.9%
1.9%
Q1 25
10.0%
3.3%
Q4 24
9.7%
0.6%
Q3 24
13.7%
4.3%
Q2 24
10.7%
1.7%
EPS (diluted)
CBT
CBT
SCL
SCL
Q1 26
$0.86
Q4 25
$1.37
$0.22
Q3 25
$0.80
$0.47
Q2 25
$1.86
$0.50
Q1 25
$1.69
$0.86
Q4 24
$1.67
$0.14
Q3 24
$2.41
$1.03
Q2 24
$1.94
$0.42

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CBT
CBT
SCL
SCL
Cash + ST InvestmentsLiquidity on hand
$230.0M
Total DebtLower is stronger
$328.4M
Stockholders' EquityBook value
$1.6B
$1.2B
Total Assets
$3.8B
$2.3B
Debt / EquityLower = less leverage
0.28×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CBT
CBT
SCL
SCL
Q1 26
Q4 25
$230.0M
$132.7M
Q3 25
$258.0M
$118.5M
Q2 25
$239.0M
$88.9M
Q1 25
$213.0M
$107.5M
Q4 24
$183.0M
$99.7M
Q3 24
$223.0M
$147.3M
Q2 24
$197.0M
$124.7M
Total Debt
CBT
CBT
SCL
SCL
Q1 26
$328.4M
Q4 25
$626.7M
Q3 25
$1.1B
$655.5M
Q2 25
$658.0M
Q1 25
$659.3M
Q4 24
$625.4M
Q3 24
$1.1B
$688.5M
Q2 24
$657.1M
Stockholders' Equity
CBT
CBT
SCL
SCL
Q1 26
$1.2B
Q4 25
$1.6B
$1.2B
Q3 25
$1.6B
$1.2B
Q2 25
$1.5B
$1.2B
Q1 25
$1.4B
$1.2B
Q4 24
$1.4B
$1.2B
Q3 24
$1.4B
$1.2B
Q2 24
$1.3B
$1.2B
Total Assets
CBT
CBT
SCL
SCL
Q1 26
$2.3B
Q4 25
$3.8B
$2.4B
Q3 25
$3.8B
$2.4B
Q2 25
$3.8B
$2.4B
Q1 25
$3.8B
$2.4B
Q4 24
$3.6B
$2.3B
Q3 24
$3.7B
$2.4B
Q2 24
$3.6B
$2.3B
Debt / Equity
CBT
CBT
SCL
SCL
Q1 26
0.28×
Q4 25
0.50×
Q3 25
0.70×
0.53×
Q2 25
0.53×
Q1 25
0.55×
Q4 24
0.53×
Q3 24
0.75×
0.56×
Q2 24
0.55×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CBT
CBT
SCL
SCL
Operating Cash FlowLast quarter
$126.0M
Free Cash FlowOCF − Capex
$57.0M
FCF MarginFCF / Revenue
6.7%
Capex IntensityCapex / Revenue
8.1%
Cash ConversionOCF / Net Profit
1.73×
TTM Free Cash FlowTrailing 4 quarters
$401.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CBT
CBT
SCL
SCL
Q1 26
Q4 25
$126.0M
$60.0M
Q3 25
$219.0M
$69.8M
Q2 25
$249.0M
$11.2M
Q1 25
$73.0M
$6.9M
Q4 24
$124.0M
$68.3M
Q3 24
$204.0M
$22.7M
Q2 24
$207.0M
$29.5M
Free Cash Flow
CBT
CBT
SCL
SCL
Q1 26
Q4 25
$57.0M
$25.4M
Q3 25
$155.0M
$40.2M
Q2 25
$188.0M
$-14.4M
Q1 25
$1.0M
$-25.8M
Q4 24
$47.0M
$32.1M
Q3 24
$112.0M
$-4.0M
Q2 24
$155.0M
$-208.0K
FCF Margin
CBT
CBT
SCL
SCL
Q1 26
Q4 25
6.7%
4.6%
Q3 25
17.2%
6.8%
Q2 25
20.4%
-2.4%
Q1 25
0.1%
-4.3%
Q4 24
4.9%
6.1%
Q3 24
11.2%
-0.7%
Q2 24
15.3%
-0.0%
Capex Intensity
CBT
CBT
SCL
SCL
Q1 26
Q4 25
8.1%
6.3%
Q3 25
7.1%
5.0%
Q2 25
6.6%
4.3%
Q1 25
7.7%
5.5%
Q4 24
8.1%
6.9%
Q3 24
9.2%
4.9%
Q2 24
5.1%
5.3%
Cash Conversion
CBT
CBT
SCL
SCL
Q1 26
Q4 25
1.73×
11.99×
Q3 25
5.09×
6.44×
Q2 25
2.47×
0.99×
Q1 25
0.78×
0.35×
Q4 24
1.33×
20.38×
Q3 24
1.49×
0.96×
Q2 24
1.90×
3.10×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CBT
CBT

Reinforcement Materials$520.0M61%
Performance Chemicals$300.0M35%
Shipping And Handling$25.0M3%
Other Products And Services$4.0M0%

SCL
SCL

Surfactants$453.7M75%
Polymers$130.0M22%
Specialty Products$20.8M3%

Related Comparisons